VK2735 Phase 2 trial (NCT06828055)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Dose Finding Study of VK2735 Oral Formulation for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition
Registry record checked
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 280
- actual
- Start
- 18 Dec 2024 (actual)
- Primary completion
- 24 Jun 2025 (actual)
- Sponsor
- Viking Therapeutics, Inc.
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Placebo Assignment | Placebo comparator | Drug: Placebo | VK2735 (Placebo) administered Daily |
| Active Assignment (Dose #1) | Experimental | Drug: VK2735 | VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily |
| Active Assignment (Dose #2) | Experimental | Drug: VK2735 | VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily |
| Active Assignment (Dose #3) | Experimental | Drug: VK2735 | VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily |
| Active Assignment (Dose #4) | Experimental | Drug: VK2735 | VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily |
| Active Assignment (Dose #5) | Experimental | Drug: VK2735 | VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily |
| Active Assignment (Dose #6) | Experimental | Drug: VK2735 | VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Percent (relative) change from baseline in body weight after 13 weeks of treatment | 13 Weeks |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Proportion of Subjects losing ≥5% and ≥10% of baseline weight at Week 13. Observed and change from baseline in body weight (kg) after 13 weeks of treatment | 13 Weeks |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Dose Finding Study of VK2735 Oral Formulation for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid ConditionClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.